Avacta hails data for faridoxorubicin to treat salivary gland cancers
(Alliance News) - Avacta Group PLC on Monday said its lead programme faridoxorubicin showed favourable safety and tolerability in patients with salivary gland cancers. Read More
| Price | 72.50p on 25-11-2025 at 06:00:01 |
|---|---|
| Change | 0.00p 0% |
| Buy | 0.00p |
| Sell | 0.00p |
| Last Trade: | Unknown 3,900.00 at 72.50p |
| Day's Volume: | 0 |
| Last Close: | 72.50p |
| Open: | 77.00p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 0.00p - 0.00p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £314.41m |
| VWAP: | 0.00p |
| Shares in Issue: | 433.66m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 3,900 | 72.50p | Ordinary |
16:32:07 - 24-Nov-25 |
| Buy* | 500 | 72.6963p | Ordinary |
16:26:29 - 24-Nov-25 |
| Buy* | 1,362 | 72.6963p | Ordinary |
16:25:53 - 24-Nov-25 |
| Buy* | 2,452 | 73.00p | Ordinary |
16:25:03 - 24-Nov-25 |
| Buy* | 5,546 | 72.6999p | Ordinary |
16:23:45 - 24-Nov-25 |
| Buy* | 5,482 | 72.7475p | Ordinary |
16:22:40 - 24-Nov-25 |
| Sell* | 50,000 | 72.05p | Ordinary |
16:22:15 - 24-Nov-25 |
| Sell* | 6,578 | 72.35p | Ordinary |
16:20:49 - 24-Nov-25 |
| Sell* | 6,911 | 72.35p | Ordinary |
16:20:24 - 24-Nov-25 |
| Sell* | 2,000 | 72.35p | Ordinary |
16:19:08 - 24-Nov-25 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 3rd Nov 2025 8:24 am | RNS | Completion of Placing and TVR |
| 27th Oct 2025 5:39 pm | RNS | Block Listing Six Monthly Return |
| 27th Oct 2025 7:00 am | RNS | Avacta presents preclinical data at AACR-NCI-EORTC |
| 23rd Oct 2025 5:00 pm | RNS-R | Notice of Investor Presentation |
| 20th Oct 2025 7:01 am | RNS | Equity fundraise of £16 million |
| 20th Oct 2025 7:00 am | RNS | Avacta Presents Phase 1a Data for Faridoxorubicin |
| 13th Oct 2025 7:00 am | RNS | Avacta to present data at EORTC-NCI-AACR |
| 30th Sep 2025 7:00 am | RNS | Interim Half Year Results 2025 |
| 15th Sep 2025 7:00 am | RNS | Notice of Interim Results |
| 9th Sep 2025 7:00 am | RNS-R | Shortlisted for AIM Awards Technology of the Year |